ConductScience.org, home

Comparison · NCT01703208-bd8e6c13

Omarigliptin 25 mg vs Placebo: Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Omarigliptin 25 mg vs Placebo: Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke). Trial comparisons, record NCT01703208-bd8e6c13. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01703208-bd8e6c13

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.05450.04560.0651wilson
Risk in group 20.05430.04540.0648wilson
Risk difference, group 1 minus group 20.000208-0.01360.014newcombe hybrid score
Risk ratio, group 1 over group 210.781.29log
Odds ratio, group 1 over group 210.7691.31log
Number needed to treat, for one more participant with the outcome on Omarigliptin 25 mg than on Placebo4,820from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Omarigliptin 25 mgOmarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly1142,092OG000
Group 2PlaceboMatching placebo to omarigliptin capsule or tablet administered once weekly.1142,100OG001

Outcome

Type
PRIMARY
Title
Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)
Description
Participants with an Event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction \[MI\], and fatal and nonfatal stroke).
Time frame
Up to 179 weeks
Population
The analysis population included all randomized participants who took at least one dose of blinded trial medication.

Source ClinicalTrials.gov

Trial

Title
A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
NCT number
NCT01703208
Phases
PHASE3
Conditions
Type 2 Diabetes Mellitus
Interventions
Omarigliptin, Placebo
Lead sponsor
Merck Sharp & Dohme LLC
Results first posted
2017-12-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01703208-bd8e6c13